Cargando…
A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
Sweet Syndrome, or acute febrile neutrophilic dermatosis, is a rare inflammatory dermatologic disorder that can be spontaneous, associated with malignancy, or drug-induced. Reports of Sweet Syndrome in gynecologic oncology patients are sparse, and the majority are thought to be malignancy-associated...
Autores principales: | Badiner, Nora, Carter, Cody, Ioffe, Yevgeniya, Hong, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040500/ https://www.ncbi.nlm.nih.gov/pubmed/36992982 http://dx.doi.org/10.1016/j.gore.2023.101162 |
Ejemplares similares
-
Searching for the source: Extraovarian primary peritoneal carcinoma presenting as chest wall masses
por: Brinker Feng, Madison, et al.
Publicado: (2023) -
Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience
por: Mercado, Kristina E., et al.
Publicado: (2023) -
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021) -
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017) -
The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)